ICON (ICLR) stock price tumbles 40% after accounting probe delays 2025 results

February 12, 2026
ICON (ICLR) stock price tumbles 40% after accounting probe delays 2025 results

New York, Feb 12, 2026, 10:04 EST — Regular session

Shares of ICON plc (NASDAQ: ICLR) plunged on Thursday following news of an audit committee probe into its accounting practices and a delay in releasing its 2025 results. The stock dropped 42%, hitting $77.73 by 10:04 a.m. EST, with a low of $67.19 earlier in the session.

ICON announced it now plans to release its fourth-quarter and full-year 2025 earnings on or before April 30, pulling back its full-year 2025 guidance during the ongoing review. This delay removes a crucial update from the earnings schedule and leaves investors uncertain about the company’s recent performance. 1

The company said preliminary findings suggest revenue for 2023 and 2024 might have been overstated by less than 2% each year, focusing on how and when sales are recorded. It also anticipates reporting one or more material weaknesses—a significant control gap that could increase the risk of errors in its financial statements. 2

The audit committee kicked off the investigation in late October following concerns raised by management, the company said. External legal counsel is leading the inquiry, backed by forensic experts and technical accounting firms. 3

ICON reported that the investigation found no evidence of customer impact from the practices examined. Chair Ciaran Murray emphasized the board’s dedication to “transparency, accountability and strong governance,” while CEO Barry Balfe confirmed the company is “implementing a series of corrective actions.” 4

Evercore ISI analyst Elizabeth Anderson paused her rating on the stock following the disclosure, warning that a mere 1% revenue adjustment in 2023 might slash earnings per share by as much as 80 cents. The report also highlighted a broad spectrum of possible results for 2024. 5

Leerink Partners analyst Michael Cherny downgraded ICON from outperform to market perform, slashing his price target to $105 from $220. He noted the stock might be “overly penal” but said he “cannot pitch this stock” until updated financials come out. 6

The full extent of the review—and if the initial findings will stand as the investigation proceeds—remains unclear. A broader restatement or additional delays might weigh on the shares further and intensify investor focus on governance and controls. 7

Investors have set their sights on April 30 for a key event: the company’s long-awaited 2025 results. They’re also awaiting updates on the audit committee investigation and the schedule for the annual Form 20-F filing. 8

Stock Market Today

  • Haleon Shares Draw Attention as FTSE 100, FTSE 350 Healthcare React
    March 24, 2026, 2:12 PM EDT. Haleon shares have come under the spotlight amid notable movements in the FTSE 100 and the FTSE 350 healthcare sector. Investors are closely watching the company's performance as it influences broader market sentiment in healthcare stocks. The FTSE 350 healthcare index, representing key players in the sector, is reacting to various factors affecting Haleon and its peers. Market participants are evaluating developments that could impact share prices and sector valuations. This focus highlights the interconnection between individual stock movements and wider index trends in the healthcare space on the London Stock Exchange.